Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03383-wSource: DataRank Database

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial is a research paper published in Cancer Immunology Immunotherapy (2023). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.36)OA: hybridTopics (58)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Amy K. Erbe ORCID,Jennifer Birstler,KyungMann Kim ORCID,Ute Hoch ORCID,Sue Currie

Live enrichment

PubMed:36823323 OpenAlex:https://openalex.org/W4321610524

National Institutes of Health

Grant: CA014520

National Institutes of Health

Grant: 1R35CA197078-01

Enhancing Antibody-directed Innate Immunity to Improve Cancer Outcome

National Institutes of Health

Grant: 5P30CA014520-18

CANCER CENTER SUPPORT

FWCI

0.36

Citation Percentile

0.5%

Citation Trend

2024

2025

hybridLicense: cc-by

journalhttps://link.springer.com/content/pdf/10.1007/s00262-023-03383-w.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00262-023-03383-w.pdf

publisherhttps://link.springer.com/article/10.1007/s00262-023-03383-w/fulltext.html

journalhttps://doi.org/10.1007/s00262-023-03383-w

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36823323

Fields of Study

Immune Cell Function and InteractionT-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers03 medical and health sciences0302 clinical medicine

MeSH Terms

NivolumabGenotypeHumansInterleukin-2LigandsNeoplasmsPolyethylene GlycolsRetrospective StudiesReceptors, IgGPolymorphism, Single NucleotideReceptors, KIR

Keywords

NivolumabGenotypeSingle-nucleotide polymorphismReceptorLigand (biochemistry)ImmunologySNPHuman leukocyte antigenInternal medicineOncologyBiologyMedicineImmunotherapyImmune systemGeneGeneticsAntigenKiller immunoglobulin-like receptor (KIR)Medical SciencesIgGBioinformatics610NK cellsLigandsPolymorphism, Single NucleotideBiomedical InformaticsPolyethylene GlycolsReceptors, KIRNeoplasmsReceptorsMedical SpecialtiesMedicine and Health SciencesHumansPolymorphismRetrospective StudiesResearchReceptors, IgGSingle NucleotideHuman leukocyte antigen (HLA)KIRBempegaldesleukinInterleukin-2

Sustainable Development Goals

SDG 0: Good health and well-being